Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Hypercalcemia Follow-up

  • Author: Mahendra Agraharkar, MD, MBBS, FACP; Chief Editor: Vecihi Batuman, MD, FACP, FASN  more...
 
Updated: Jun 23, 2015
 

Further Outpatient Care

In most cases, follow-up care is dictated by the etiology of hypercalcemia. If the hypercalcemia is related to malignancy, efforts are directed towards treating the neoplasm.

Oral phosphates have only a limited role in the treatment of hypercalcemia and are increasingly replaced by bisphosphonates. However, when phosphates are used, especially for treating chronic hypercalcemia, attention should be paid to hyperphosphatemia and the calcium and phosphate product because this tends to increase the risk of metastatic calcification.

Restriction of dietary calcium and administration of glucocorticoids remains the preferred treatment for hypercalcemia due to sarcoidosis and vitamin D intoxication.

 
Contributor Information and Disclosures
Author

Mahendra Agraharkar, MD, MBBS, FACP FASN, Clinical Associate Professor of Medicine, Baylor College of Medicine; President and CEO, Space City Associates of Nephrology

Mahendra Agraharkar, MD, MBBS, FACP is a member of the following medical societies: American College of Physicians, American Society of Nephrology, National Kidney Foundation

Disclosure: Received ownership interest/medical directorship from South Shore DaVita Dialysis Center for other; Received ownership/medical directorship from Space City Dialysis /American Renal Associates for same; Received ownership interest from US Renal Care for other.

Coauthor(s)

O David Dellinger, III, MD Assistant Professor, Departments of Family Medicine and Internal Medicine, University of Alabama School of Medicine at Birmingham

O David Dellinger, III, MD is a member of the following medical societies: American Academy of Hospice and Palliative Medicine, American College of Physicians-American Society of Internal Medicine, American Geriatrics Society, AMDA - The Society for Post-Acute and Long-Term Care Medicine, American Society of Addiction Medicine

Disclosure: Nothing to disclose.

Arun Kumar Gangakhedkar, MD, FRACP Consultant in General Pediatrics, Starship Children's Hospital/Waitakere Hospital, New Zealand

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Christie P Thomas, MBBS, FRCP, FASN, FAHA Professor, Department of Internal Medicine, Division of Nephrology, Departments of Pediatrics and Obstetrics and Gynecology, Medical Director, Kidney and Kidney/Pancreas Transplant Program, University of Iowa Hospitals and Clinics

Christie P Thomas, MBBS, FRCP, FASN, FAHA is a member of the following medical societies: American College of Physicians, American Heart Association, American Society of Nephrology, Royal College of Physicians

Disclosure: Nothing to disclose.

Chief Editor

Vecihi Batuman, MD, FACP, FASN Huberwald Professor of Medicine, Section of Nephrology-Hypertension, Tulane University School of Medicine; Chief, Renal Section, Southeast Louisiana Veterans Health Care System

Vecihi Batuman, MD, FACP, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, International Society of Nephrology

Disclosure: Nothing to disclose.

References
  1. McKay CP, Portale A. Emerging topics in pediatric bone and mineral disorders 2008. Semin Nephrol. 2009 Jul. 29(4):370-8. [Medline].

  2. Guarnieri V, Canaff L, Yun FH, et al. Calcium-Sensing Receptor (CASR) Mutations in Hypercalcemic States: Studies from a Single Endocrine Clinic Over Three Years. J Clin Endocrinol Metab. 2010 Feb 17. [Medline].

  3. Nissen PH, Christensen SE, Wallace A, et al. Multiplex ligation-dependent probe amplification (MLPA) screening for exon copy number variation in the calcium sensing receptor gene: no large rearrangements identified in patients with calcium metabolic disorders. Clin Endocrinol (Oxf). 2009 Nov 11. [Medline].

  4. Luna-Cabrera F, Justicia-Rull EA, Caricol-Pérez MP, et al. Incidence of hypercalcemia, hypercalciuria and related factors in patients treated with recombinant human parathyroid hormone (1-84). Minerva Med. 2012 Apr. 103(2):103-10. [Medline].

  5. Vanstone MB, Oberfield SE, Shader L, Ardeshirpour L, Carpenter TO. Hypercalcemia in Children Receiving Pharmacologic Doses of Vitamin D. Pediatrics. 2012 Mar 12. [Medline].

  6. Royer AM, Maclellan RA, Daniel Stanley J, Willingham TB, Heath Giles W. Hypercalcemia in the emergency department: a missed opportunity. Am Surg. 2014 Aug. 80(8):732-5. [Medline].

  7. Cafforio P, Savonarola A, Stucci S, De Matteo M, Tucci M, Brunetti AE, et al. PTHrP produced by myeloma plasma cells regulates their survival and pro-osteoclast activity for bone disease progression. J Bone Miner Res. 2014 Jan. 29(1):55-66. [Medline].

  8. Alsirafy SA, Sroor MY, Al-Shahri MZ. Hypercalcemia in advanced head and neck squamous cell carcinoma: prevalence and potential impact on palliative care. J Support Oncol. 2009 Sep-Oct. 7(5):154-7. [Medline].

  9. Makras P, Papapoulos SE. Medical treatment of hypercalcaemia. Hormones (Athens). 2009 Apr-Jun. 8(2):83-95. [Medline]. [Full Text].

  10. Brooks M. FDA Approves New Indication for Denosumab (Xgeva). Medscape Medical News. Available at http://www.medscape.com/viewarticle/836252. Accessed: December 13, 2014.

  11. Hu MI, Glezerman IG, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, et al. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab. 2014 Sep. 99(9):3144-52. [Medline]. [Full Text].

  12. Bergenfelz AO, Jansson SK, Wallin GK, et al. Impact of modern techniques on short-term outcome after surgery for primary hyperparathyroidism: a multicenter study comprising 2,708 patients. Langenbecks Arch Surg. 2009 Jul 18. [Medline].

  13. Low TH, Clark J, Gao K, et al. Outcome of parathyroidectomy for patients with renal disease and hyperparathyroidism: predictors for recurrent hyperparathyroidism. ANZ J Surg. 2009 May. 79(5):378-82. [Medline].

  14. Padhi D, Harris R. Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009. 48(5):303-11. [Medline].

  15. Marcocci C, Chanson P, Shoback D, et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab. 2009 Jun 2. [Medline].

  16. al Zahrani A, Levine MA. Primary hyperparathyroidism. Lancet. 1997 Apr 26. 349(9060):1233-8. [Medline].

  17. Allerheiligen DA, Schoeber J, Houston RE. Hyperparathyroidism. Am Fam Physician. 1998 Apr 15. 57(8):1795-802, 1807-8. [Medline].

  18. Carroll MF, Schade DS. A practical approach to hypercalcemia. Am Fam Physician. 2003 May 1. 67(9):1959-66. [Medline].

  19. Falk S, Fallon M. ABC of palliative care. Emergencies. BMJ. 1997 Dec 6. 315(7121):1525-8. [Medline].

  20. Ganong CA, Kappy MS. Hypercalcemia. In: Berman S, ed. Pediatric Decision Making. 3rd ed. St. Louis, Mo: Mosby-Year Book; 1996:. 128-31.

  21. Hay WW Jr, Hayward AR, Levin MJ, Sondheimer JM, eds. Current Pediatric Diagnosis and Treatment. 14th ed. Stamford, Conn: Appleton & Lange; 1999:. 830-1.

  22. Hoenderop JG, Nilius B, Bindels RJ. Molecular mechanism of active Ca2+ reabsorption in the distal nephron. Annu Rev Physiol. 2002. 64:529-49. [Medline].

  23. Inzucchi SE. Management of hypercalcemia. Diagnostic workup, therapeutic options for hyperparathyroidism and other common causes. Postgrad Med. 2004 May. 115(5):27-36. [Medline].

  24. Lteif AN, Zimmerman D. Bisphosphonates for treatment of childhood hypercalcemia. Pediatrics. 1998 Oct. 102(4 Pt 1):990-3. [Medline].

  25. Mundy GR, Guise TA. Hypercalcemia of malignancy. Am J Med. 1997 Aug. 103(2):134-45. [Medline].

  26. Pearce SH. Calcium homeostasis and disorders of the calcium-sensing receptor. J R Coll Physicians Lond. 1998 Jan-Feb. 32(1):10-4. [Medline].

  27. Postlethwaite RJ. Clinical Pediatric Nephrology. 2nd ed. New York, NY: Butterworth Heinemann; 1994.

  28. Renton P. Radiology of rickets, osteomalacia and hyperparathyroidism. Hosp Med. 1998 May. 59(5):399-403. [Medline].

  29. Rogers MJ, Watts DJ, Russell RG. Overview of bisphosphonates. Cancer. 1997 Oct 15. 80(8 Suppl):1652-60. [Medline].

  30. Sharma OP. Vitamin D, calcium, and sarcoidosis. Chest. 1996. 109(2):535-539. [Medline].

  31. Strewler GJ. The physiology of parathyroid hormone-related protein. N Engl J Med. 2000 Jan 20. 342(3):177-85. [Medline].

Previous
Next
 
Investigations flowchart.
Vitamin D metabolism.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.